Overview

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

Status:
RECRUITING

Trial end date:
2031-07-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide

Phase:

PHASE3

Details

Lead Sponsor:

Vir Biotechnology, Inc.

Treatments:

bulevirtide